文献速递肿瘤 PET/CT

肿瘤学示踪剂动力学分析原理,第I部分:原理与方法学概览

Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology.
PubMed 文献 · J Nucl Med · 2022-01-01

本文为继续教育综述第I部分,介绍肿瘤PET示踪剂动力学分析的基本原理与方法,指出临床常规单时间点静态成像未充分利用PET可提供的信息,动力学分析可增进对体内癌症生物学的理解、改善临床决策并指导静态图像定量指标解读。

要点

  • PET可无创成像体内区域癌症生物学,靶向代谢、血流、增殖及肿瘤受体表达或配体结合等过程。
  • 临床常规静态成像仅在注射后远离示踪剂的时间点单次采集,未利用PET可提供的全部信息。
  • 仅依赖静态成像获得的示踪剂指标可能导致误导性结果,动力学分析可弥补此不足。

核心结论

  • 动力学分析可增进对体内癌症生物学的理解、改善临床决策方法,并指导静态图像定量指标的解读。

研究设计与样本

  • 本文为2部分继续教育综述的第1部分,阐述肿瘤PET示踪剂动力学分析的原理,第2部分将给出具体实施示例并突出其优于静态成像之处。

主要发现

  • 通过设计靶向癌症相关生物学过程(如癌症代谢、血流、增殖、肿瘤受体表达或配体结合)的放射性示踪剂,PET可检测癌症播散、表征癌症表型并评估治疗反应。
  • 使用放射性葡萄糖类似物18F-FDG成像葡萄糖代谢在以上3项任务中均有广泛应用,在癌症诊疗中发挥重要作用。
  • 当前临床实践采用远离示踪剂注射的单时间点成像(即静态成像),未使用PET癌症成像可提供的全部信息,尤其难以回答癌症检测之外的问题。
  • 仅依赖静态成像获得的示踪剂指标可能导致误导性结果。

临床怎么用

  • 本文旨在向核医学临床医生介绍肿瘤成像中动力学分析的基本概念,说明动力学分析如何增进对体内癌症生物学的理解、改善临床决策方法并指导静态图像定量指标的解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) describe principles of PET tracer kinetic analysis for oncologic applications; (2) list methods used for PET kinetic analysis for oncology; and (3) discuss application of kinetic modeling for cancer-specific diagnostic needs.Financial Disclosure: This work was supported by KL2 TR001879, R01 CA211337, R01 CA113941, R33 CA225310, Komen SAC130060, R50 CA211270, and K01 DA040023. Dr. Pantel is a consultant or advisor for Progenics and Blue Earth Diagnostics and is a meeting participant or lecturer for Blue Earth Diagnostics. Dr. Mankoff is on the scientific advisory boards of GE Healthcare, Philips Healthcare, Reflexion, and ImaginAb and is the owner of Trevarx; his wife is the chief executive officer of Trevarx. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through March 2025PET enables noninvasive imaging of regional in vivo cancer biology. By engineering a radiotracer to target specific biologic processes of relevance to cancer (e.g., cancer metabolism, blood flow, proliferation, and tumor receptor expression or ligand binding), PET can detect cancer spread, characterize the cancer phenotype, and assess its response to treatment. For example, imaging of glucose metabolism using the radiolabeled glucose analog 18F-FDG has widespread applications to all 3 of these tasks and plays an important role in cancer care. However, the current clinical practice of imaging at a single time point remote from tracer injection (i.e., static imaging) does not use all the information that PET cancer imaging can provide, especially to address questions beyond cancer detection. Reliance on tracer measures obtained only from static imaging may also lead to misleading results. In this 2-part continuing education paper, we describe the principles of tracer kinetic analysis for oncologic PET (part 1), followed by examples of specific implementations of kinetic analysis for cancer PET imaging that highlight the added benefits over static imaging (part 2). This review is designed to introduce nuclear medicine clinicians to basic concepts of kinetic analysis in oncologic imaging, with a goal of illustrating how kinetic analysis can augment our understanding of in vivo cancer biology, improve our approach to clinical decision making, and guide the interpretation of quantitative measures derived from static images.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pantel AR, Viswanath V, Muzi M, et al. Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology. J Nucl Med. 2022. PMID: 35232879. doi:10.2967/jnumed.121.263518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。